---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-008940"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2023-02-27T23:59:59+00:00"
generated_at: "2026-06-18T23:15:01.528892+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma reports Q4 2022 net loss of $66.7M; cash $399.7M; pipeline on track for 2023 regulatory filings

## Summary
- Net loss $66.7M ($0.92/sh) in Q4 2022 vs $44.2M ($0.69) in Q4 2021; full-year net loss $221.9M ($3.26) vs $169.1M ($2.67).
- Cash, cash equivalents and investments $399.7M as of Dec 31, 2022; expected runway through 2024.
- Plans BLA submissions: LAD-I in Q2 2023, Fanconi Anemia in Q4 2023; Phase 2 pivotal for Danon Disease (RP-A501) starts Q2 2023.
- FDA granted RMAT designation for RP-A501 (Danon Disease); acquired Renovacor in Dec 2022 adding BAG3-DCM program.
- Raised $197.7M in 2022 via follow-on, ATM, and Renovacor cash; appointed new board member and executives.

## SEC filing metadata
- accession: 0001140361-23-008940
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2023-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/0001140361-23-008940-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/brhc10048939_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-008940
- JSON: https://secwatch.observer/filing/0001140361-23-008940.json
- Plain text: https://secwatch.observer/filing/0001140361-23-008940.txt

## Key facts
- Earnings Releases
  ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter and year ended December 31, 2022.
  - Period: the quarter and year ended December 31, 2022
  - Result: reported results
  source text: On February 27, 2023, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter and year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1281895/000114036123008940/0001140361-23-008940-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.